Cargando…

Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population

BACKGROUND: The c.1124_1127delTTCA p.(Ile375Argfs*43) pathogenic variant is the most frequently identified molecular defect in the KCNQ1 gene in the cardiogenetics clinic of the Antwerp University Hospital. This variant was observed in nine families presenting with either Jervell-Lange-Nielsen syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieliwonczyk, Ewa, Alaerts, Maaike, Simons, Eline, Snyders, Dirk, Nijak, Aleksandra, Vandendriessche, Bert, Schepers, Dorien, Akdeniz, Dogan, Van Craenenbroeck, Emeline, Knaepen, Katleen, Rabaut, Laura, Heidbuchel, Hein, Van Laer, Lut, Saenen, Johan, Labro, Alain J., Loeys, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887867/
https://www.ncbi.nlm.nih.gov/pubmed/36721196
http://dx.doi.org/10.1186/s13023-023-02618-4
_version_ 1784880423690567680
author Sieliwonczyk, Ewa
Alaerts, Maaike
Simons, Eline
Snyders, Dirk
Nijak, Aleksandra
Vandendriessche, Bert
Schepers, Dorien
Akdeniz, Dogan
Van Craenenbroeck, Emeline
Knaepen, Katleen
Rabaut, Laura
Heidbuchel, Hein
Van Laer, Lut
Saenen, Johan
Labro, Alain J.
Loeys, Bart
author_facet Sieliwonczyk, Ewa
Alaerts, Maaike
Simons, Eline
Snyders, Dirk
Nijak, Aleksandra
Vandendriessche, Bert
Schepers, Dorien
Akdeniz, Dogan
Van Craenenbroeck, Emeline
Knaepen, Katleen
Rabaut, Laura
Heidbuchel, Hein
Van Laer, Lut
Saenen, Johan
Labro, Alain J.
Loeys, Bart
author_sort Sieliwonczyk, Ewa
collection PubMed
description BACKGROUND: The c.1124_1127delTTCA p.(Ile375Argfs*43) pathogenic variant is the most frequently identified molecular defect in the KCNQ1 gene in the cardiogenetics clinic of the Antwerp University Hospital. This variant was observed in nine families presenting with either Jervell-Lange-Nielsen syndrome or long QT syndrome (LQTS). Here, we report on the molecular, clinical and functional characterization of the KCNQ1 c.1124_1127delTTCA variant. RESULTS: Forty-one heterozygous variant harboring individuals demonstrated a predominantly mild clinical and electrophysiological phenotype, compared to individuals harboring other KCNQ1 pathogenic variants (5% symptomatic before 40 years of age, compared to 24% and 29% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers, respectively, 33% with QTc ≤ 440 ms compared to 10% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers). The LQTS phenotype was most comparable to that observed for the Swedish p.(Arg518*) founder mutation (7% symptomatic at any age, compared to 17% in p.(Arg518*) variant carriers, 33% with QTc ≤ 440 ms compared to 16% in p.(Arg518*) variant carriers). Surprisingly, short tandem repeat analysis did not reveal a common haplotype for all families. One KCNQ1 c.1124_1127delTTCA harboring patient was diagnosed with Brugada syndrome (BrS). The hypothesis of a LQTS/BrS overlap syndrome was supported by electrophysiological evidence for both loss-of-function and gain-of-function (acceleration of channel kinetics) in a heterologous expression system. However, BrS phenotypes were not identified in other affected individuals and allelic KCNQ1 expression testing in patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) showed nonsense mediated decay of the c.1124_1127delTTCA allele. CONCLUSIONS: The c.1124_1127delTTCA frameshift variant shows a high prevalence in our region, despite not being confirmed as a founder mutation. This variant leads to a mild LQTS phenotype in the heterozygous state. Despite initial evidence for a gain-of-function effect based on in vitro electrophysiological assessment in CHO cells and expression of the KCNQ1 c.1124_1127delTTCA allele in patient blood cells, additional testing in iPSC-CMs showed lack of expression of the mutant allele. This suggests haploinsufficiency as the pathogenic mechanism. Nonetheless, as inter-individual differences in allele expression in (iPSC-) cardiomyocytes have not been assessed, a modifying effect on the BrS phenotype through potassium current modulation cannot be excluded. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02618-4.
format Online
Article
Text
id pubmed-9887867
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98878672023-02-01 Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population Sieliwonczyk, Ewa Alaerts, Maaike Simons, Eline Snyders, Dirk Nijak, Aleksandra Vandendriessche, Bert Schepers, Dorien Akdeniz, Dogan Van Craenenbroeck, Emeline Knaepen, Katleen Rabaut, Laura Heidbuchel, Hein Van Laer, Lut Saenen, Johan Labro, Alain J. Loeys, Bart Orphanet J Rare Dis Research BACKGROUND: The c.1124_1127delTTCA p.(Ile375Argfs*43) pathogenic variant is the most frequently identified molecular defect in the KCNQ1 gene in the cardiogenetics clinic of the Antwerp University Hospital. This variant was observed in nine families presenting with either Jervell-Lange-Nielsen syndrome or long QT syndrome (LQTS). Here, we report on the molecular, clinical and functional characterization of the KCNQ1 c.1124_1127delTTCA variant. RESULTS: Forty-one heterozygous variant harboring individuals demonstrated a predominantly mild clinical and electrophysiological phenotype, compared to individuals harboring other KCNQ1 pathogenic variants (5% symptomatic before 40 years of age, compared to 24% and 29% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers, respectively, 33% with QTc ≤ 440 ms compared to 10% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers). The LQTS phenotype was most comparable to that observed for the Swedish p.(Arg518*) founder mutation (7% symptomatic at any age, compared to 17% in p.(Arg518*) variant carriers, 33% with QTc ≤ 440 ms compared to 16% in p.(Arg518*) variant carriers). Surprisingly, short tandem repeat analysis did not reveal a common haplotype for all families. One KCNQ1 c.1124_1127delTTCA harboring patient was diagnosed with Brugada syndrome (BrS). The hypothesis of a LQTS/BrS overlap syndrome was supported by electrophysiological evidence for both loss-of-function and gain-of-function (acceleration of channel kinetics) in a heterologous expression system. However, BrS phenotypes were not identified in other affected individuals and allelic KCNQ1 expression testing in patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) showed nonsense mediated decay of the c.1124_1127delTTCA allele. CONCLUSIONS: The c.1124_1127delTTCA frameshift variant shows a high prevalence in our region, despite not being confirmed as a founder mutation. This variant leads to a mild LQTS phenotype in the heterozygous state. Despite initial evidence for a gain-of-function effect based on in vitro electrophysiological assessment in CHO cells and expression of the KCNQ1 c.1124_1127delTTCA allele in patient blood cells, additional testing in iPSC-CMs showed lack of expression of the mutant allele. This suggests haploinsufficiency as the pathogenic mechanism. Nonetheless, as inter-individual differences in allele expression in (iPSC-) cardiomyocytes have not been assessed, a modifying effect on the BrS phenotype through potassium current modulation cannot be excluded. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02618-4. BioMed Central 2023-01-31 /pmc/articles/PMC9887867/ /pubmed/36721196 http://dx.doi.org/10.1186/s13023-023-02618-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sieliwonczyk, Ewa
Alaerts, Maaike
Simons, Eline
Snyders, Dirk
Nijak, Aleksandra
Vandendriessche, Bert
Schepers, Dorien
Akdeniz, Dogan
Van Craenenbroeck, Emeline
Knaepen, Katleen
Rabaut, Laura
Heidbuchel, Hein
Van Laer, Lut
Saenen, Johan
Labro, Alain J.
Loeys, Bart
Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population
title Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population
title_full Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population
title_fullStr Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population
title_full_unstemmed Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population
title_short Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population
title_sort clinical and functional characterisation of a recurrent kcnq1 variant in the belgian population
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887867/
https://www.ncbi.nlm.nih.gov/pubmed/36721196
http://dx.doi.org/10.1186/s13023-023-02618-4
work_keys_str_mv AT sieliwonczykewa clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT alaertsmaaike clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT simonseline clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT snydersdirk clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT nijakaleksandra clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT vandendriesschebert clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT schepersdorien clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT akdenizdogan clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT vancraenenbroeckemeline clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT knaepenkatleen clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT rabautlaura clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT heidbuchelhein clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT vanlaerlut clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT saenenjohan clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT labroalainj clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation
AT loeysbart clinicalandfunctionalcharacterisationofarecurrentkcnq1variantinthebelgianpopulation